利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.045 秒)

    Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
    2.
    发明授权
    Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells 有权
    突变的抗CD22抗体对表达CD22的白血病细胞的亲和力增加

    公开(公告)号：US07777019B2

    公开(公告)日：2010-08-17

    申请号：US12030828

    申请日：2008-02-13

    申请人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert J. Kreitman

    发明人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert J. Kreitman

    IPC分类号： C07H21/04 ,  A61K39/395 ,  C07K16/00

    CPC分类号： C07K16/2803 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6875 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624

    摘要： Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.

    摘要翻译： 重组免疫毒素是由与细菌或植物毒素融合的抗体的Fv结构域组成的融合蛋白。 RFB4（Fv）-PE38是靶向在B细胞和B细胞恶性肿瘤上表达的CD22的免疫毒素。 与RFB4相比，本发明提供了具有改善的结合B细胞和B细胞恶性肿瘤的CD22抗原的能力的抗体和抗体片段。 用本发明的抗体和抗体片段制备的免疫毒素对表达CD22的癌细胞具有改善的细胞毒性。 将这些抗体并入可用于药物的嵌合免疫毒素分子中的组合物和用于抑制白血病和淋巴瘤细胞生长和增殖的方法。

    IMMUNOGENIC PEPTIDES FOR THE TREATMENT OF PROSTATE AND BREAST CANCER
    3.
    发明申请
    IMMUNOGENIC PEPTIDES FOR THE TREATMENT OF PROSTATE AND BREAST CANCER 有权
    用于治疗前列腺癌和乳腺癌的免疫抑制剂

    公开(公告)号：US20090208518A1

    公开(公告)日：2009-08-20

    申请号：US12430837

    申请日：2009-04-27

    申请人： Jay A. Berzofsky ,  SangKon Oh ,  Ira Pastan

    发明人： Jay A. Berzofsky ,  SangKon Oh ,  Ira Pastan

    IPC分类号： A61K39/00 ,  C07K7/00 ,  C12N15/11 ,  C12N15/79 ,  C12N5/10 ,  A61P35/00 ,  A61K31/711 ,  C12N5/00 ,  G01N33/566 ,  A61K38/08

    CPC分类号： C07K14/4748 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/57

    摘要： Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1. Several specific, non-limiting examples of these polypeptides are set forth as SEQ ID NOs: 3-7. Nucleic acids encoding these polypeptides, and host cells transfected with these nucleic acids, are also disclosed. Methods of using these polypeptides, and polynucleotides encoding these polypeptides, for the treatment of breast and prostate cancer are also disclosed.

    摘要翻译： 本文公开了免疫原性T细胞受体γ替代阅读框蛋白（TARP）多肽。 这些免疫原性TARP多肽包括SEQ ID NO：9所示的氨基酸序列的9个连续氨基酸，并且不包含SEQ ID NO：1的氨基酸1-26或氨基酸38-58。几个具体的，非限制性的 这些多肽的实例如SEQ ID NO：3-7所示。 还公开了编码这些多肽的核酸和用这些核酸转染的宿主细胞。 还公开了使用这些多肽的方法和编码这些多肽的多核苷酸用于治疗乳腺癌和前列腺癌。

    T-cell receptorγ alternate reading frame protein, (TARP) and uses thereof
    5.
    发明授权
    T-cell receptorγ alternate reading frame protein, (TARP) and uses thereof 有权
    T细胞接受体交替阅读框蛋白（TARP）及其用途

    公开(公告)号：US07052703B1

    公开(公告)日：2006-05-30

    申请号：US10031158

    申请日：2000-07-12

    申请人： Ira Pastan ,  Magnus Essand ,  Byungkook Lee ,  George Vasmatzis ,  Curt Wolfgang ,  Ulrich Brinkmann

    发明人： Ira Pastan ,  Magnus Essand ,  Byungkook Lee ,  George Vasmatzis ,  Curt Wolfgang ,  Ulrich Brinkmann

    IPC分类号： A61K39/00

    CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K39/00

    摘要： This invention provides nucleic acids containing sequences from a TCRγ transcript from prostate epithelial cells and many breast cancer cells and a T-cell receptor gamma Alternate Reading frame Protein (“TARP”) expressed from the translation of those sequences. Vaccines made from TARP are useful in raising immune responses to cells in which the protein is expressed, including prostate cancer cells and cells of many breast cancers. The invention also provides methods for diagnosing the presence of prostate cancer and TARP-expressing breast cancers, as well as methods of administering TARP and nucleic acids encoding TARP to subjects.

    摘要翻译： 本发明提供了含有来自前列腺上皮细胞的TCRγ转录物和许多乳腺癌细胞的序列的核酸，以及从这些序列翻译表达的T细胞受体γ替代阅读框架蛋白（“TARP”）。 由TARP制成的疫苗可用于提高蛋白质表达细胞的免疫应答，包括前列腺癌细胞和许多乳腺癌细胞。 本发明还提供了用于诊断前列腺癌和TARP表达乳腺癌的存在的方法，以及将TARP和编码TARP的核酸给予受试者的方法。

    Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
    6.
    发明申请
    Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use 有权
    包括FV分子的抗体和对间皮素具有高结合亲和力的免疫缀合物及其使用方法

    公开(公告)号：US20050214304A1

    公开(公告)日：2005-09-29

    申请号：US10973718

    申请日：2004-10-25

    申请人： Ira Pastan ,  Partha Chowdhury

    发明人： Ira Pastan ,  Partha Chowdhury

    IPC分类号： A61K47/48 ,  C07K16/30 ,  G01N33/574 ,  A61K39/395 ,  C07H21/04 ,  C12N1/21 ,  C12N15/74

    CPC分类号： G01N33/57492 ,  A61K47/6829 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/3069 ,  C07K2317/565 ,  G01N33/57449

    摘要： Mesothelin ins a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.

    摘要翻译： 间皮素含有存在于卵巢癌，间皮瘤和其他几种类型人类癌症表面的分化抗原。 因为在正常组织中，间皮素仅存在于间皮细胞上，它代表抗体介导的细胞毒性剂递送的良好靶标。 本发明涉及抗间皮素抗体，包括对间皮素具有特别高亲和力的Fv分子和使用它们的免疫缀合物。 还描述了使用抗体的诊断和治疗方法。 抗间皮素抗体非常适合于诊断和治疗卵巢癌，胃癌，鳞状细胞癌，间皮瘤等表达间皮素的恶性细胞癌。

    Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
    7.
    发明申请
    Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells 有权
    突变的抗cd22抗体与对表达CD22的白血病细胞的亲和性增加

    公开(公告)号：US20050118182A1

    公开(公告)日：2005-06-02

    申请号：US10490535

    申请日：2002-09-25

    申请人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert Kreitman

    发明人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert Kreitman

    IPC分类号： A61K47/48 ,  C07K16/28 ,  A61K39/40 ,  C07K16/46

    CPC分类号： C07K16/2803 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6875 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624

    摘要： Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.

    摘要翻译： 重组免疫毒素是由与细菌或植物毒素融合的抗体的Fv结构域组成的融合蛋白。 RFB4（Fv）-PE38是靶向在B细胞和B细胞恶性肿瘤上表达的CD22的免疫毒素。 与RFB4相比，本发明提供了具有改善的结合B细胞和B细胞恶性肿瘤的CD22抗原的能力的抗体和抗体片段。 用本发明的抗体和抗体片段制备的免疫毒素对表达CD22的癌细胞具有改善的细胞毒性。 将这些抗体并入可用于药物的嵌合免疫毒素分子中的组合物和用于抑制白血病和淋巴瘤细胞生长和增殖的方法。

    IL-13 receptor specific chimeric proteins and uses thereof
    8.
    发明授权
    IL-13 receptor specific chimeric proteins and uses thereof 失效
    IL-13受体特异性嵌合蛋白及其用途

    公开(公告)号：US06518061B1

    公开(公告)日：2003-02-11

    申请号：US08913370

    申请日：1998-02-17

    申请人： Raj K. Puri ,  Waldemar Debinski ,  Ira Pastan ,  Nicholas Obiri

    发明人： Raj K. Puri ,  Waldemar Debinski ,  Ira Pastan ,  Nicholas Obiri

    IPC分类号： C12N1574

    CPC分类号： C07K14/21 ,  A61K38/00 ,  A61K47/642 ,  A61K47/6849 ,  A61K2039/505 ,  C07K14/5437 ,  C07K16/2866 ,  C07K2319/00

    摘要： The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell bearing an IL-13 receptor. The method involves providing a chimeric molecule that comprises an effector molecule attached to a circularly permuted IL-13 (“cpIL-13”) that specifically binds an IL-13 receptor and contacting the tumor cell with the chimeric molecule. The compositions include chimeric molecules comprising effector molecules such as modified Pseudomonas exotoxin attached to a cpIL-13. The invention further provides vectors encoding the chimeric molecules.

    摘要翻译： 本发明提供了将效应分子特异性递送至携带IL-13受体的肿瘤细胞的方法和组合物。 该方法包括提供嵌合分子，其包含连接到特异性结合IL-13受体并使肿瘤细胞与嵌合分子接触的循环置换的IL-13（“cpIL-13”）的效应分子。 组合物包括包含效应分子的嵌合分子，例如连接到cpIL-13的修饰的假单胞菌外毒素。 本发明进一步提供编码嵌合分子的载体。